Klea Holding (ALKLH) Fair Value & Analysis
Healthcare · FR · Market cap €53.6M
Fair value as of: Jul 14, 2026
From 24 valuation models · updated 27 days ago
Fair value updated Jul 14, 2026, revised from €0.0800 to €0.1500 (+87.5%) since Jun 26, 2026. Share price −10.9% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from €0.1100 (bear) to €0.1900 (bull), base €0.1500. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 65/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 14, 2026.
How to read this chart
60‑month range €0.0862 – €0.5430 · fair‑value band €0.1100 – €0.1900 · the €0.1572 price screens above the €0.1500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 14, 2026.
Analysis
Klea Holding (ALKLH) currently trades at €0.1572, while our model-based Fair Value estimate is €0.1500, implying the stock looks roughly 4.6% fairly valued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Klea Holding generated revenue of €22.2M at a net margin of 10.3%. Revenue grew 13.9% year over year. It earns a return on equity of 8.2%. The stock trades on a trailing P/E of 19.7. Fundamentals as of Jul 14, 2026
Our scenario range runs from €0.1100 (bear case) to €0.1900 (bull case); at €0.1572, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -5%, ALKLH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (€0.2000) versus Asset-Based (€0.0600). Highest evidence: Growth DCF (80).
Notify me when ALKLH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Klea Holding SA, together with its subsidiaries, develops health technologies and services in France, the United Arab Emirates, Saudi Arabia, and the European Union. It operates digitalized medical centers that provide administrative screenings for residency and work visas, preventive health check-ups, and medical fitness tests under the Smart Salem brand.
Full company description
Klea Holding SA, together with its subsidiaries, develops health technologies and services in France, the United Arab Emirates, Saudi Arabia, and the European Union. It operates digitalized medical centers that provide administrative screenings for residency and work visas, preventive health check-ups, and medical fitness tests under the Smart Salem brand. Additionally, the company engages in the production of pharmaceuticals. The company was formerly known as Visiomed Group SA and changed its name to Klea Holding SA in June 2024. Klea Holding SA was founded in 2007 and is headquartered in Paris, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Klea Holding reported revenue of €22.2M in FY2025 versus €7.2M in FY2021, a compound +32.6%/yr. Reported net income was €2.3M in FY2025.
Watch ALKLH: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Klea Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Klea Holding (ALKLH) overvalued or undervalued?
What is the fair value of ALKLH?
What is the quality score of ALKLH?
What is the revenue of Klea Holding (ALKLH)?
What is the net profit margin of ALKLH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Klea Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.